XML 31 R12.htm IDEA: XBRL DOCUMENT v3.22.4
Revenues
 12 Months Ended
Dec. 31, 2022
Revenue from Contract with Customer [Abstract]  
Revenues Revenues
We operate in one business segment: human therapeutics. Therefore, results of our operations are reported on a consolidated basis for purposes of segment reporting, consistent with internal management reporting. Revenues by product and by geographic area, based on customers’ locations, are presented below. The majority of ROW revenues relates to products sold in Europe.
Revenues were as follows (in millions):
Year ended December 31, 2022Year ended December 31, 2021Year ended December 31, 2020
U.S.ROWTotalU.S.ROWTotalU.S.ROWTotal
ENBREL$4,044 $73 $4,117 $4,352 $113 $4,465 $4,855 $141 $4,996 
Prolia2,465 1,163 3,628 2,150 1,098 3,248 1,830 933 2,763 
Otezla1,886 402 2,288 1,804 445 2,249 1,790 405 2,195 
XGEVA1,480 534 2,014 1,434 584 2,018 1,405 494 1,899 
Aranesp521 900 1,421 537 943 1,480 629 939 1,568 
Nplate848 459 1,307 566 461 1,027 485 365 850 
Repatha
608 688 1,296 557 560 1,117 459 428 887 
KYPROLIS850 397 1,247 736 372 1,108 710 355 1,065 
Neulasta959 167 1,126 1,514 220 1,734 2,001 292 2,293 
EVENITY533 254 787 331 199 530 191 159 350 
Other products(1)
3,549 2,021 5,570 3,305 2,016 5,321 3,630 1,744 5,374 
Total product sales(2)
17,743 7,058 24,801 17,286 7,011 24,297 17,985 6,255 24,240 
Other revenues852 670 1,522 908 774 1,682 511 673 1,184 
Total revenues$18,595 $7,728 $26,323 $18,194 $7,785 $25,979 $18,496 $6,928 $25,424 
____________
(1)    Consists of product sales of our non-principal products, as well as our Gensenta and Bergamo subsidiaries.
(2)    Hedging gains and losses, which are included in product sales, were not material for the years ended December 31, 2022, 2021 and 2020.
In the United States, we sell primarily to pharmaceutical wholesale distributors that we use as the principal means of distributing our products to healthcare providers. Outside the United States, we sell principally to healthcare providers and/or pharmaceutical wholesale distributors depending on the distribution practice in each country. We monitor the financial condition of our larger customers and limit our credit exposure by setting credit limits and, in certain circumstances, by requiring letters of credit or obtaining credit insurance.
We had product sales to three customers that individually accounted for more than 10% of total revenues for each of the years ended December 31, 2022, 2021 and 2020. For the year ended December 31, 2022, on a combined basis, these customers accounted for 82% of total gross revenues as shown in the following table. Certain information with respect to these customers was as follows (dollar amounts in millions):
Years ended December 31,
202220212020
McKesson Corporation:
Gross product sales$17,305 $15,187 $13,779 
% of total gross revenues35 %33 %32 %
AmerisourceBergen Corporation:
Gross product sales$15,443 $14,783 $14,743 
% of total gross revenues31 %32 %34 %
Cardinal Health, Inc.:
Gross product sales$8,319 $7,681 $7,332 
% of total gross revenues16 %17 %17 %
As of December 31, 2022 and 2021, amounts due from these three customers each exceeded 10% of gross trade receivables and accounted for 75% and 73%, respectively, of net trade receivables on a combined basis. As of December 31, 2022 and 2021, 26% and 27%, respectively, of net trade receivables were due from customers located outside the United States, the majority of which were from Europe. Our total allowance for doubtful accounts as of December 31, 2022 and 2021, was not material.